Search - tctmd.com

Displaying 21 - 40 of 47

Sort: Relevancy | Date

Presentation ESC 2022

International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches - Chronic Kidney Disease EXTENDed Follow-up: Survival at 5 years of Follow-up

Presenter: Sripal Bangalore

August 29, 2022

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

Presentation ESC 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presenter: Otavio Berwanger

August 29, 2022

Presentation ESC 2022

Impact on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: a meta-analysis of individual patient data from seven multicenter randomized clinical trials

Presenter: Giuseppe Gargiulo

August 29, 2022

Presentation ESC 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presenter: John Eikelboom

August 29, 2022

Presentation ESC 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presenter: John H. Alexander

August 28, 2022

Presentation ESC 2022

Smartphone-based screening for atrial fibrillation (eBRAVE-AF) – A pragmatic siteless digital randomized clinical trial

Presenter: Axel Bauer

August 28, 2022

Presentation ESC 2022

Coronary Atherosclerotic Plaque Activity and Future Coronary Events

Presenter: David Newby

August 28, 2022

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

Shelley Wood

August 28, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Todd Neale

August 28, 2022

Presentation ESC 2022

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Presenter: Divaka Perera

August 27, 2022

Presentation ESC 2022

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Presenter: Divaka Perera

August 27, 2022

News Conference News ESC 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

Shelley Wood

August 27, 2022

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Conference News ESC 2022

Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX

Caitlin E. Cox

August 27, 2022

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

L.A. McKeown

August 27, 2022

News Conference News ESC 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

Shelley Wood

August 27, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

Advertisement

International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches - Chronic Kidney Disease EXTENDed Follow-up: Survival at 5 years of Follow-up

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Impact on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: a meta-analysis of individual patient data from seven multicenter randomized clinical trials

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Smartphone-based screening for atrial fibrillation (eBRAVE-AF) – A pragmatic siteless digital randomized clinical trial

Coronary Atherosclerotic Plaque Activity and Future Coronary Events

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content